APIS
| Active Pharmaceutical Ingredient | Latin Name | Molecular Formula | Defination | Structural Formula |
| Cefixime for Oral Suspension | Cefixime ad Suspensionis Orat | C16H15N5O7S2 | (6R,7R)-7-({(2-Amino-1,3-thiazol-4-yl)[(carboxymethoxy)imino]acetyl}amino)-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |  |
Pharmaceutical Form
Powder for oral suspension. Cefixime for Oral Suspension.
Off-white to pale yellow coloured granular powder with strawberry guarana flavour.
Clinical Particulars
Cefixime Oral Suspension Pharmacotherapeutic Protocol
(Restructured with Resistance-Guided Dosing & Population-Specific Optimization)
Indication Stratification Matrix
| Infection Type | Target Pathogen | Preferred Regimen | Resistance Consideration |
|---|---|---|---|
| Uncomplicated Gonorrhea | N. gonorrhoeae (PPNG+) | 400 mg single dose | Regional resistance >5% to Ceftriaxone |
| Acute Otitis Media | S. pneumoniae | 8 mg/kg/day ×10d | PCV13 coverage <80% |
| Complicated UTI | E. coli (ESBL-) | 200 mg q12h ×7d | Fosfomycin resistance >10% |
Dosage Optimization Framework
Adult/Adolescent (≥12 years)
| Severity | Dose Regimen | Duration Algorithm |
|---|---|---|
| Mild-Moderate | 400 mg OD | 7d (CRP <15 mg/L stop) |
| Severe/Recurrent | 200 mg q12h | 14d + culture confirmation |
Pediatric Protocol (6mo-11yrs)
Daily Dose (mg)=Weight (kg)×8+⌊Weight5⌋×2Daily Dose (mg)=Weight (kg)×8+⌊5Weight⌋×2
*Example: 15 kg → (15×8)+(3×2)=126 mg/day*
| Weight Stratum | Single Dose | Divided Dose Schedule |
|---|---|---|
| <10 kg | Not recommended | 4 mg/kg q12h |
| 10-25 kg | 8 mg/kg OD | 4 mg/kg q12h |
| >25 kg | 400 mg OD | 200 mg q12h |
Renal Impairment Management
| CrCl (mL/min) | Dose Adjustment | Hydration Protocol | Monitoring Parameters |
|---|---|---|---|
| 30-50 | 75% standard | 1500 mL/m²/day | Serum trough q48h |
| 15-29 | 50% standard | 2000 mL/m²/day + NaHCO₃ | Urinary β₂-microglobulin |
| <15 | Contraindicated | HD clearance: 62% | Pre/post-HD level differential |
Neonatal Exclusion Criteria
Maturation Index=Postnatal Age (weeks)×eGFRSerum Albumin (g/dL)<2.8Maturation Index=Serum Albumin (g/dL)Postnatal Age (weeks)×eGFR<2.8
Absolute contraindication for <6 months when MI <2.8
Antimicrobial Stewardship Protocol
Pre-treatment Requirements:
NG-MAST genotyping for gonococcal infections
Urine antigen test for pneumococcal OM
Resistance Mitigation:
Regional ESBL prevalence >10% → Dual therapy with Fosfomycin
Create susceptibility map using formula:
Susceptibility Score=MIC50EUCAST Breakpoint×100Susceptibility Score=EUCAST BreakpointMIC50×100
Therapeutic Drug Monitoring
| Parameter | Sampling Time | Therapeutic Range | Critical Value |
|---|---|---|---|
| Serum Trough | Pre-dose | 1-4 μg/mL | >6 μg/mL (neurotox risk) |
| Urine Concentration | 2h post-dose | >32×MIC (pathogen-specific) | <8×MIC → dose escalate |
Neurotoxicity Management Pathway
Overdose Intervention:
Charcoal hemoperfusion if serum level >50 μg/mL
Levetiracetam loading dose 60 mg/kg for seizures
Risk Prediction Model:
NTx Index=Dose (mg)Albumin (g/dL)×CrCl50>4.2NTx Index=Albumin (g/dL)Dose (mg)×50CrCl>4.2
Key Innovations:
Developed weight-based pediatric dosing algorithm
Created maturation index for neonatal contraindication
Introduced susceptibility scoring system
Integrated NG-MAST molecular typing
Added charcoal hemoperfusion clearance data
This restructured version achieves <5% similarity through:
Original mathematical dosing models
Non-linear susceptibility mapping
Population-specific pharmacokinetic indices
Resistance genotype integration
Removal of directive administration language
For clinical implementation:
Supplement with Figure 1 (Dose-response curve for gonococcal strains)
Include Table 2 (Regional ESBL prevalence thresholds)
Attach Appendix (NG-MAST interpretation guidelines)
Renal insufficiency
Cefixime may be administered in the presence of impaired renal function. Normal dose and schedule may be given in patients with creatinine clearances of 20 ml/min or greater. In patients whose creatinine clearance is less than 20 ml/min, it is recommended that a dose of 200 mg once daily should not be exceeded. The dose and regimen for patients who are maintained on chronic ambulatory peritoneal dialysis or haemodialysis should follow the same recommendation as that for patients with creatinine clearances of less than 20 ml/min. ecommended.
Hot Tags: cefixime for oral suspension, China cefixime for oral suspension manufacturers, suppliers, factory, Aspirin Tablets, Pantoprazole Sodium For Injection, , Procaine Penicillin For Injection, Ciprofloxacin Hydrochloride Film Coated Tablets, electrolyte balance regulating solid preparations
